Plains GP Holdings, L.P.
PAGPPlains GP Holdings, L.P.'s earnings have outrun its stock. EPS grew +154.9% in a year against a +51.4% price move.
The sharpest disagreement: annual EPS moved +154.9% against a +51.4% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (24 weeks in). Underneath, the last four quarters read improving, and 249% of the last 2 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Plains GP Holdings, L.P. trades at $27.7, in a confirmed uptrend and 24 weeks into that stage. That is +18.4% against its own 200-day average. It sits at 97% of a 52-week range of $17 to $28. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks.
Today the stock is in a confirmed uptrend — week 24 of stage 2. At $27.7 it trades +18.4% versus its 200-day average and sits at 97% of its 52-week range ($17–$28).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +7% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 10 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Plains GP Holdings, L.P. trades at 17.5× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 17.5× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +154.9% against a +51.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +20.1%/yr price move, ~−6.6%/yr came from earnings growth and ~+26.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Plains GP Holdings, L.P. reads as deteriorating on its fundamental arc. Deteriorating — revenue and profit growth are shrinking (revenue growth −7.2% latest against +4.1% at its 12-quarter best), ROCE lifting at 5.9%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −9.5% | −8.3% | — | — |
| EPS | +154.9% | +14.8% | — | — |
| Stock price | +51.4% | +20.1% | +22.2% | −0.9% |
4-Factor Sector Score
43.4/100 — rank 19 of 30 in Oil & Gas Midstream · 64% evidence confidence
Plains GP Holdings, L.P. scores 43.4 out of 100 against the 30 companies it is compared with in Oil & Gas Midstream, ranking 19. Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 12.8 + 4 + 9.4 + 17.2 = 43.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Plains GP Holdings, L.P. reported $12.5 B of revenue in the Mar 26 quarter, +8.6% year on year. Over 4 years it has compounded at 1.3% a year. The last full year, FY25, came in at $44.3 B. The last four reported quarters add to $45.3 B.
FY25 revenue came in at $44.3 B (−9.5% on the year), capping 4 years at 1.3% compound. The latest quarter (Mar 26) printed $12.5 B, +8.6% year on year.
Pace check: the last four quarters averaged −6.8% growth against the decade's 1.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −7.2% over the last 4 quarters against −1.9%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Plains GP Holdings, L.P.'s operating margin is 3.2% in the Mar 26 quarter, +0.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 1.8% to 3.2%. The current quarter sits inside that band.
The latest quarter's operating margin is 3.2%, +0.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.8%–3.2%, and FY25's 3.2% is the top of that band — a record year.
Why the margin moved: operating margin went +0.2 pp year on year while gross margin went −0.5 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Plains GP Holdings, L.P. earned $0.1 B of net profit in the Mar 26 quarter. The full FY25 year was a loss of $0.4 B. That is 0.8% of the quarter's revenue. The same quarter a year earlier lost $0.1 B. 7 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.1 B, null year on year. On the full year, FY25 printed $−0.4 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years 249% of Plains GP Holdings, L.P.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $5.9 B of operating cash against $−0.4 B of profit. After $0.6 B of capital spending, $5.2 B was left as free cash.
FY25: operating cash of $5.9 B against reported profit of $−0.4 B, leaving free cash of $5.2 B after $0.6 B of capital spending. Across the last 2 fiscal years the conversion rate is 249% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Plains GP Holdings, L.P. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 1.5% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Plains GP Holdings, L.P. earns a ROE of −3% in FY25. Return on invested capital clears the cost of that capital by −0.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −0.9% net margin on 1.41× asset turns.
FY25 ROE is −3%.
🚨 Why the return is what it is — the wiring (FY25): −0.9% net margin × 1.41× asset turns × 2.20× balance-sheet leverage ≈ −2.8% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 5.5% − 5.8% = a −0.3 pp spread. The 5.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Plains GP Holdings, L.P. paid $1.59 per share over the last four reported quarters, up 9.9% on a year ago. The most recent declaration was $0.42 for Mar 26. Against the current price of $27.7 that is a trailing yield of 5.74%, measured on dividends already paid rather than on a forecast.
Plains GP Holdings, L.P. paid $1.59 per share across the last four reported quarters, most recently $0.42 for Mar 26. That is up 9.9% against the same quarter a year earlier. Against the current price of $27.7 the trailing twelve months work out to 5.74% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Plains GP Holdings, L.P. carries total debt of $11.6 B against shareholder equity of $13.9 B as of Mar 26, a debt-to-equity of 0.83. On the annual view that ratio went from 0.67 in FY21 to 0.81 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $11.6 B against shareholder equity of $13.9 B — a debt-to-equity of 0.83. On the annual view, debt-to-equity went from 0.67 (FY21) to 0.81 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
9.1% of Plains GP Holdings, L.P.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 10.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 9.1% of the float is sold short, and at typical trading volumes it would take about 10.3 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Plains GP Holdings, L.P.: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Frontline plcFRO | 80.9/100Sector-leading setup81% evidence | BREAKING OUT | 29.2/35 Revenue 18.5% · PAT 100% · OPM change 60.1 pp 83% evidence | 16.8/25 ROCE 10.8% · OPM 81.9% 76% evidence | 15.5/20 P/E 8.6× · PEG 0.19 65% evidence | 19.4/20 RS sector 41.1% · RS bench 54.4% · 1Y 131.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 29.2 + 16.8 + 15.5 + 19.4 = 80.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2International Seaways, Inc.INSW | 78.2/100Favorable setup81% evidence | BREAKING OUT | 27.0/35 Revenue 14.5% · PAT 69.3% · OPM change 57.6 pp 83% evidence | 16.5/25 ROCE 11.2% · OPM 89.9% 76% evidence | 16.4/20 P/E 6.6× · PEG 0.09 65% evidence | 18.3/20 RS sector 32.3% · RS bench 44.6% · 1Y 129.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27 + 16.5 + 16.4 + 18.3 = 78.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3BW LPG LimitedBWLP | 73.5/100Favorable setup81% evidence | BREAKING OUT | 24.7/35 Revenue 5.1% · PAT 31.4% · OPM change 23.6 pp 83% evidence | 14.5/25 ROCE 8% · OPM 26.2% 76% evidence | 15.4/20 P/E 7.3× · PEG 0.28 65% evidence | 18.9/20 RS sector 27.3% · RS bench 39.6% · 1Y 68.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 14.5 + 15.4 + 18.9 = 73.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Venture Global, Inc.VG | 69.6/100Favorable setup85% evidence | BREAKING OUT | 23.4/35 Revenue 100% · PAT 100% · OPM change 14.3 pp 95% evidence | 11.7/25 ROCE 4.3% · OPM 47.8% 76% evidence | 15.8/20 P/E 8.8× · PEG 0.14 65% evidence | 18.7/20 RS sector 10.9% · RS bench 21.1% · 1Y 10.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.4 + 11.7 + 15.8 + 18.7 = 69.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Cmb.Tech NVCMBT | 67.0/100Favorable setup71% evidence | BREAKING OUT | 24.0/35 Revenue 100% · PAT 12.5% · OPM change 40.9 pp 83% evidence | 12.7/25 ROCE 5.8% · OPM 84.6% 76% evidence | 11.2/20 P/E 7.9× · PEG — 15% evidence | 19.1/20 RS sector 27.5% · RS bench 40% · 1Y 113.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 12.7 + 11.2 + 19.1 = 67 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Cheniere Energy Partners, L.P.CQP | 66.7/100Favorable setup85% evidence | BREAKING OUT | 26.8/35 Revenue 15.4% · PAT 28.1% · OPM change 22.8 pp 95% evidence | 15.1/25 ROCE 8.5% · OPM 51.9% 76% evidence | 14.7/20 P/E 11.1× · PEG 0.33 65% evidence | 10.1/20 RS sector -7.3% · RS bench 2.7% · 1Y 25.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 26.8 + 15.1 + 14.7 + 10.1 = 66.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Scorpio Tankers Inc.STNG | 61.9/100Thin evidence · provisional58% evidence | TURNING | 23.1/35 Revenue — · PAT — · OPM change 42 pp 45% evidence | 14.9/25 ROCE 9.8% · OPM 70.2% 76% evidence | 11.5/20 P/E 4.3× · PEG — 15% evidence | 12.4/20 RS sector 4.5% · RS bench 15.2% · 1Y 45.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 14.9 + 11.5 + 12.4 = 61.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Cheniere Energy, Inc.LNG | 59.5/100Mixed-positive evidence85% evidence | BREAKING OUT | 19.8/35 Revenue 17.5% · PAT -11.8% · OPM change 20.3 pp 95% evidence | 14.8/25 ROCE 10.2% · OPM 74.8% 76% evidence | 12.0/20 P/E 17.8× · PEG 0.9 65% evidence | 12.9/20 RS sector -4.8% · RS bench 5.2% · 1Y 15.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 14.8 + 12 + 12.9 = 59.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Targa Resources Corp.TRGP | 57.3/100Mixed-positive evidence85% evidence | BREAKING OUT | 18.7/35 Revenue -2% · PAT 29.6% · OPM change 3.5 pp 95% evidence | 12.4/25 ROCE 5.4% · OPM 27.8% 76% evidence | 12.4/20 P/E 25.6× · PEG 0.51 65% evidence | 13.8/20 RS sector 7.3% · RS bench 17.7% · 1Y 73.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 18.7 + 12.4 + 12.4 + 13.8 = 57.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Energy Transfer LPET | 55.8/100Mixed-positive evidence85% evidence | BREAKING OUT | 20.3/35 Revenue 33.3% · PAT 16.1% · OPM change -1.6 pp 95% evidence | 10.5/25 ROCE 3% · OPM 10.4% 76% evidence | 12.3/20 P/E 13× · PEG 0.93 65% evidence | 12.7/20 RS sector -4.3% · RS bench 6.1% · 1Y 22%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.3 + 10.5 + 12.3 + 12.7 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Plains All American Pipeline, L.P.PAA | 52.8/100Mixed-positive evidence81% evidence | TURNING | 16.8/35 Revenue -7.1% · PAT 45.4% · OPM change 0.1 pp 83% evidence | 6.5/25 ROCE 1.7% · OPM 3.2% 76% evidence | 13.1/20 P/E 18.5× · PEG 0.49 65% evidence | 16.4/20 RS sector 4.1% · RS bench 14.8% · 1Y 49.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 6.5 + 13.1 + 16.4 = 52.8 · Decision use: Price leads the evidence: RS versus the benchmark is 14.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 12Western Midstream Partners, LPWES | 51.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 13.8/35 Revenue 11.4% · PAT -6.5% · OPM change -2.9 pp 83% evidence | 13.3/25 ROCE 3.8% · OPM 41.8% 76% evidence | 15.0/20 P/E 13.5× · PEG 0.17 65% evidence | 9.8/20 RS sector -6.6% · RS bench 3.7% · 1Y 22.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13.3 + 15 + 9.8 = 51.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Kinetik Holdings Inc.KNTK | 49.8/100Mixed-negative evidence81% evidence | BREAKING OUT | 15.5/35 Revenue 9.3% · PAT 100% · OPM change -5.2 pp 83% evidence | 4.7/25 ROCE -0.1% · OPM -0.9% 76% evidence | 14.0/20 P/E 19.8× · PEG 0.27 65% evidence | 15.6/20 RS sector 3.4% · RS bench 14% · 1Y 25.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 4.7 + 14 + 15.6 = 49.8 · Decision use: Price leads the evidence: RS versus the benchmark is 14%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Golar LNG LimitedGLNG | 49.4/100Mixed-negative evidence81% evidence | TURNING | 27.8/35 Revenue 81.5% · PAT 100% · OPM change 76.5 pp 83% evidence | 10.3/25 ROCE 2.7% · OPM 81.8% 76% evidence | 4.4/20 P/E 42.3× · PEG 2.76 65% evidence | 6.9/20 RS sector -7.1% · RS bench 2.4% · 1Y 28.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 27.8 + 10.3 + 4.4 + 6.9 = 49.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.1% and the one-year return is 28.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 15ONEOK, Inc.OKE | 47.9/100Mixed-negative evidence85% evidence | TURNING | 16.1/35 Revenue 40.8% · PAT 13.1% · OPM change -4.9 pp 95% evidence | 10.3/25 ROCE 2.7% · OPM 13.2% 76% evidence | 10.8/20 P/E 15× · PEG 1.15 65% evidence | 10.7/20 RS sector -5.3% · RS bench 4.6% · 1Y 29.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 10.3 + 10.8 + 10.7 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Hess Midstream LPHESM | 46.7/100Mixed-negative evidence81% evidence | TURNING | 12.2/35 Revenue 7% · PAT 3.6% · OPM change -1.1 pp 83% evidence | 14.8/25 ROCE 5.8% · OPM 61% 76% evidence | 11.8/20 P/E 13.4× · PEG 1.01 65% evidence | 7.9/20 RS sector -10% · RS bench -0.1% · 1Y 11.9%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 14.8 + 11.8 + 7.9 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Kinder Morgan, Inc.KMI | 46.4/100Mixed-negative evidence85% evidence | ASLEEP | 21.6/35 Revenue 12.5% · PAT 26.1% · OPM change 1.6 pp 95% evidence | 10.3/25 ROCE 2% · OPM 30.1% 76% evidence | 12.4/20 P/E 20.5× · PEG 0.73 65% evidence | 2.1/20 RS sector -14.9% · RS bench -5.7% · 1Y 12.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 10.3 + 12.4 + 2.1 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18The Williams Companies, Inc.WMB | 45.5/100Mixed-negative evidence85% evidence | ASLEEP | 22.1/35 Revenue 8.7% · PAT 26.2% · OPM change 4.7 pp 95% evidence | 10.9/25 ROCE 2.3% · OPM 38.7% 76% evidence | 9.7/20 P/E 29.6× · PEG 1.11 65% evidence | 2.8/20 RS sector -12.8% · RS bench -3.5% · 1Y 18%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 10.9 + 9.7 + 2.8 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Plains GP Holdings, L.P.this pagePAGP | 43.4/100Mixed-negative evidence64% evidence | BREAKING OUT | 12.8/35 Revenue -7.1% · PAT — · OPM change 0.1 pp 62% evidence | 4.0/25 ROCE 1.6% · OPM 3.2% 76% evidence | 9.4/20 P/E 25× · PEG — 15% evidence | 17.2/20 RS sector 5.6% · RS bench 16.3% · 1Y 51.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 4 + 9.4 + 17.2 = 43.4 · Decision use: Price leads the evidence: RS versus the benchmark is 16.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Pembina Pipeline CorporationPBA | 43.3/100Mixed-negative evidence85% evidence | TURNING | 9.5/35 Revenue -1.3% · PAT -4.2% · OPM change 0 pp 95% evidence | 14.6/25 ROCE 7.7% · OPM 34% 76% evidence | 13.3/20 P/E 23.1× · PEG 0.33 65% evidence | 5.9/20 RS sector -8.9% · RS bench 0.9% · 1Y 17.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 9.5 + 14.6 + 13.3 + 5.9 = 43.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21South Bow CorporationSOBO | 42.7/100Mixed-negative evidence81% evidence | ASLEEP | 12.7/35 Revenue -4.6% · PAT 44.5% · OPM change -3.1 pp 83% evidence | 9.8/25 ROCE 1.7% · OPM 32.6% 76% evidence | 13.5/20 P/E 16.4× · PEG 0.36 65% evidence | 6.7/20 RS sector -6.1% · RS bench 3.7% · 1Y 27.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 12.7 + 9.8 + 13.5 + 6.7 = 42.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22MPLX LPMPLX | 40.8/100Mixed-negative evidence85% evidence | BREAKING OUT | 12.2/35 Revenue 4.8% · PAT 9.6% · OPM change -1.4 pp 95% evidence | 12.6/25 ROCE 3.2% · OPM 38.3% 76% evidence | 11.1/20 P/E 12.1× · PEG 1.16 65% evidence | 4.9/20 RS sector -12.5% · RS bench -2.6% · 1Y 15.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 12.6 + 11.1 + 4.9 = 40.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Enterprise Products Partners L.P.EPD | 40.6/100Mixed-negative evidence85% evidence | TURNING | 13.8/35 Revenue 6.8% · PAT 7.5% · OPM change -3.5 pp 95% evidence | 11.5/25 ROCE 3.5% · OPM 12.3% 76% evidence | 8.9/20 P/E 12.7× · PEG 1.8 65% evidence | 6.4/20 RS sector -9.4% · RS bench 0.4% · 1Y 20.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 11.5 + 8.9 + 6.4 = 40.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Antero Midstream CorporationAM | 40.4/100Thin evidence · provisional58% evidence | ASLEEP | 15.8/35 Revenue — · PAT — · OPM change -0.9 pp 45% evidence | 13.0/25 ROCE 3.1% · OPM 60% 76% evidence | 9.1/20 P/E 27.1× · PEG — 15% evidence | 2.5/20 RS sector -13% · RS bench -3.7% · 1Y 14%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 13 + 9.1 + 2.5 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25DT Midstream, Inc.DTM | 37.6/100Thin evidence · provisional58% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 10.7/25 ROCE 1.8% · OPM 49.4% 76% evidence | 8.6/20 P/E 32.1× · PEG — 15% evidence | 0.3/20 RS sector -18.9% · RS bench -10.1% · 1Y 16.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 10.7 + 8.6 + 0.3 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Viper Energy, Inc.VNOM | 35.4/100Mixed-negative evidence71% evidence | ASLEEP | 11.4/35 Revenue 84.3% · PAT -121.9% · OPM change -13.8 pp 83% evidence | 10.8/25 ROCE 2.8% · OPM 49.5% 76% evidence | 10.1/20 P/E 15.8× · PEG — 15% evidence | 3.1/20 RS sector -14.1% · RS bench -4.8% · 1Y 15.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.4 + 10.8 + 10.1 + 3.1 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27TC Energy CorporationTRP | 34.0/100Adverse evidence85% evidence | ASLEEP | 13.0/35 Revenue 9.7% · PAT -14.8% · OPM change 0.9 pp 95% evidence | 8.3/25 ROCE 1.6% · OPM 44.3% 76% evidence | 11.9/20 P/E 28.1× · PEG 0.7 65% evidence | 0.8/20 RS sector -15.3% · RS bench -6.1% · 1Y 16.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 8.3 + 11.9 + 0.8 = 34 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Excelerate Energy, Inc.EE | 31.7/100Adverse evidence81% evidence | FADING | 13.6/35 Revenue 39.4% · PAT -6.8% · OPM change -2 pp 83% evidence | 8.9/25 ROCE 2.5% · OPM 18.9% 76% evidence | 4.0/20 P/E 27.2× · PEG 3.91 65% evidence | 5.2/20 RS sector -9% · RS bench 0.5% · 1Y 49.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 8.9 + 4 + 5.2 = 31.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Enbridge Inc.ENB | 24.3/100Adverse evidence85% evidence | BASING | 13.4/35 Revenue 29.5% · PAT -8% · OPM change -5.5 pp 95% evidence | 6.4/25 ROCE 1.4% · OPM 9.9% 76% evidence | 4.2/20 P/E 29.7× · PEG 2.88 65% evidence | 0.3/20 RS sector -20.8% · RS bench -12% · 1Y -2.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 6.4 + 4.2 + 0.3 = 24.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30SunocoCorp LLCSUNC | 50.8/100Thin evidence · provisional23% evidence | BREAKING OUT | 18.4/35 Revenue — · PAT — · OPM change 2.3 pp 10% evidence | 12.4/25 ROCE 6.8% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 18.4 + 12.4 + 10 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Plains GP Holdings, L.P.'s stock price today?
Plains GP Holdings, L.P. trades at $27.7, +51.4% over the past year. The company is valued at $6.0 B. The stock sits at 97% of its 52-week range of $17–$28, +18.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 24 weeks in. — as of 17 September 2026.
What were Plains GP Holdings, L.P.'s latest quarterly results?
Plains GP Holdings, L.P. reported revenue of $12.5 B and net profit of $0.1 B for the Mar 26 quarter. Earnings per share were $0.10. The operating margin was 3.2%, 0.2 pp higher than a year earlier. — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s revenue?
Plains GP Holdings, L.P. reported revenue of $12.5 B in the Mar 26 quarter, +8.6% year on year. For the full FY25 fiscal year, revenue was $44.3 B (−9.5%). Over the last 4 years revenue compounded at 1.3% a year. — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s profit?
Plains GP Holdings, L.P. earned $0.1 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.4 B. The operating margin ran 3.2% in the latest quarter. — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s market cap?
Plains GP Holdings, L.P.'s market capitalisation is $6.0 B at a stock price of $27.7. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
Does Plains GP Holdings, L.P. pay a dividend?
Yes — Plains GP Holdings, L.P. declared $0.42 per share for Mar 26, and $1.59 per share across the last four reported quarters. The latest quarter is up 9.9% on the same quarter a year earlier. — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s dividend per share?
Plains GP Holdings, L.P.'s most recently declared dividend is $0.42 per share for Mar 26, giving $1.59 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s dividend yield?
Plains GP Holdings, L.P.'s trailing dividend yield is 5.74%: $1.59 declared per share across the last four reported quarters, against a share price of $27.7. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
How is Plains GP Holdings, L.P. performing?
Plains GP Holdings, L.P. is in a confirmed uptrend, 24 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 10 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Plains GP Holdings, L.P. in?
Deteriorating — revenue and profit growth are shrinking (revenue growth −7.2% latest against +4.1% at its 12-quarter best), ROCE lifting at 5.9%. The read comes from the last 12 quarters of growth (revenue growth −7.2% latest, profit growth −400.0% latest, eps growth +32.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Plains GP Holdings, L.P. in an uptrend?
Yes — the price is in a confirmed uptrend (week 24 of stage 2), trading +18.4% versus its 200-day average and at 97% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Plains GP Holdings, L.P. beating the market?
On recent form, yes — Plains GP Holdings, L.P. has been ahead of the S&P 500 on a trailing-13-week view for 10 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +7% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will Plains GP Holdings, L.P.'s stock price go up?
This page publishes no price forecast for Plains GP Holdings, L.P. What it measures instead: the stock price is $27.7, the price is in a confirmed uptrend 24 weeks in. Direction is not something this site claims to know. — as of 17 September 2026.
Is the market betting against Plains GP Holdings, L.P.?
Somewhat — short interest is 9.1% of Plains GP Holdings, L.P.'s tradable float, about 10.3 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Plains GP Holdings, L.P. have too much debt?
It is moderate — Plains GP Holdings, L.P.'s debt-to-equity is 0.56. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s capex?
Plains GP Holdings, L.P. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.6 B. — as of 17 September 2026.
What is Plains GP Holdings, L.P.'s cash flow?
Plains GP Holdings, L.P. generated $5.9 B of operating cash flow in FY25 and $5.2 B of free cash flow after $0.6 B of capital spending. Reported profit that year was $−0.4 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Plains GP Holdings, L.P.'s profit real cash?
Yes — over the last 2 fiscal years, 249% of Plains GP Holdings, L.P.'s reported profit arrived as operating cash. Though the latest year ran at -1542% — the trend is the thing to watch. In FY25, operating cash was $5.9 B against reported profit of $−0.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
Where is Plains GP Holdings, L.P. in its business cycle?
Plains GP Holdings, L.P.'s FY25 operating margin was 3.2%, against a 5-year band of 1.8%–3.2%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 3.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Plains GP Holdings, L.P. story?
The sharpest disagreement: annual EPS moved +154.9% against a +51.4% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Plains GP Holdings, L.P. a stock worth studying right now?
This is not investment advice. The machine read: Plains GP Holdings, L.P.'s earnings have outrun its stock. EPS grew +154.9% in a year against a +51.4% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!